[Subrenal capsule assay, a new sensitivity test for antitumor agents].
The subrenal capsule assay (SRCA) has been developed by Bogden. This simple method using fresh human tumor has much more approximation with clinical procedure than other sensitivity tests. Even from our as yet limited small experiences, its high evaluability and high specificity are promising. Problems inherent to the actual assay and its limitations were reviewed and discussed, including our trial with bone marrow puncture specimens of leukemia, our evaluation criteria and assay-clinical correlations. This method will be widely utilized in several fields of cancer treatment in the near future.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D007668:Kidney; D007680:Kidney Neoplasms / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D051379:Mice; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000473:pathology
D000970:Antineoplastic Agents